Alternative Model-Based Translational Drug Development

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 25 June 2024 | Viewed by 900

Special Issue Editors

E-Mail Website
Guest Editor
Laboratory of Cardiometabolic Pharmacology, Department of Pharmacology, Federal University of Parana, Curitiba 81530-900, PR, Brazil
Interests: pharmacology; cardio-renal pharmacology; medicinal plants; ethnopharmacology; hepatic diseases; metabolic diseases

E-Mail Website
Guest Editor
Laboratory of Cardiovascular Pharmacology (LaFaC), Federal University of Grande Dourados (UFGD), Rodovia Dourados-Itahum, km 12, P.O. Box 533, 79.804-970, Dourados, MS, Brazil
Interests: antihypertensive; antiatherogenic; cardioprotective; diuretic; lipid-lowering; vasodilator
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The quest for effective and safe drug delivery systems has been a driving force in pharmaceutical research. Delivering medications efficiently and accurately to their intended targets is crucial for maximizing therapeutic outcomes while minimizing adverse effects. Recently, there has been a growing emphasis on exploring innovative and alternative models to revolutionize drug delivery. Traditional approaches to drug delivery have often faced challenges, such as limited efficacy, poor bioavailability, and off-target effects. These limitations have prompted researchers and scientists to explore new avenues for drug delivery that can overcome these hurdles and provide improved therapeutic options for patients. One area that has gained significant attention is the intersection between drug formulation and translational medicine. Translational medicine bridges the gap between laboratory discoveries and their practical application in clinical settings. By incorporating translational medicine principles into drug formulation, researchers aim to enhance the development and delivery of pharmaceutical formulations, ultimately leading to better patient outcomes.

This Special Issue aims to shed light on the latest advancements in alternative drug delivery models and their potential implications for translational medicine. We will explore how these innovative approaches can improve the efficiency of drug formulations, promote personalized medicine, and address the specific needs of individual patients. By highlighting the importance of this research area, we aim to inspire further exploration and collaboration among scientists, clinicians, and pharmaceutical experts. Ultimately, our collective efforts in advancing drug delivery systems have the potential to transform the field of medicine, revolutionize treatment approaches, and enhance patient care.

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following:

  • Recent developments in nanotechnology-based drug delivery systems, including nanoparticles, liposomes, and micelles.
  • Alternative models for drug delivery research, such as organoids, microfluidic systems, and computational modeling.
  • Bioengineering strategies for personalized medicine, such as 3D printing of drug delivery devices and organs-on-chips.
  • Development of patient-specific drug delivery systems, considering factors like genetic variations and disease-specific characteristics.
  • Design and evaluation of preclinical models that better mimic human physiology and predict clinical outcomes.
  • Development of novel targeting agents and strategies to improve drug accumulation at specific disease sites.
  • Case studies on the clinical application of targeted drug delivery systems, highlighting their efficacy and potential impact on patient outcomes.
  • Application of alternative models in studying drug transport, absorption, and distribution.

We look forward to receiving your contributions. 

Dr. Francislaine Aparecida Dos Reis Lívero
Dr. Arquimedes Gasparotto Junior
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • pharmaceutical preparations
  • drug compounding
  • drug delivery systems
  • translation medicine
  • alternative models
  • preclinical studies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


15 pages, 4384 KiB  
In Vitro Human Liver Model for Toxicity Assessment with Clinical and Preclinical Instrumentation
by Eneko Madorran, Lidija Kocbek Šaherl, Mateja Rakuša and Miha Munda
Pharmaceutics 2024, 16(5), 607; - 29 Apr 2024
Cited by 1 | Viewed by 604
The existing in vitro toxicological models lack translational potential, which makes difficult the application of gathered information to clinical usage. To tackle this issue, we built a model with four different types of primary liver cells: hepatic sinusoidal endothelial cells, hepatic stellate cells, [...] Read more.
The existing in vitro toxicological models lack translational potential, which makes difficult the application of gathered information to clinical usage. To tackle this issue, we built a model with four different types of primary liver cells: hepatic sinusoidal endothelial cells, hepatic stellate cells, Kupffer cells and hepatocytes. We cultured them in different combinations of composition and volumes of cell medium, hepatocyte proportions of total cells and additions of extracellular matrixes. We added rifampicin (RIF), ibuprofen (IBU) and 5-fluorouracil (5-FU) to this model and observed the microanatomy and physiology changes for a week with preclinical and clinical instruments. Among the different model configurations, we selected the feature combination of the in vitro model that had similar biomarker values to those measured in clinical diagnostics. When we exposed the selected model configuration to RIF, IBU and 5-FU, we observed similar glucose, triglyceride and albumin dynamics as in vivo (from clinical data). Therefore, we have built an in vitro liver model that resembles the liver microenvironment, and we have analysed it with clinical instrumentation to facilitate data translation. Furthermore, during these observations, we found that Kupffer and LSEC cells are suitable candidates for the search for clinical diagnostic markers of liver function. Full article
(This article belongs to the Special Issue Alternative Model-Based Translational Drug Development)
Show Figures

Figure 1

Back to TopTop